CAP IASLC AMP MOLECULAR TESTING GUIDELINE

The IASLC, the College of American Pathologists (CAP), and the Association for Molecular Pathology (AMP) have developed an evidence-based guideline, “Molecular Testing Guideline for the Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors,” which establishes standards for EGFR and ALK testing, helping to guide targeted therapies. The guideline was released April 3, 2013, in Archives of Pathology & Laboratory Medicine, the Journal of Thoracic Oncology, and the Journal of Molecular Diagnostics.

 

The IASLC offers the following resources:

 

• The full article is on the JTO Website
• Downloadable summary of the recommendations
• Patient Guide 
• Frequently Asked Questions
• Slide deck of the webcast
• Webcast with the Lead Authors 

 

new webinar series

 

NOVEL AGENTS AND BIOMARKER-DRIVEN THERAPIES FOR PERSONALIZED TREATMENT OF ADVANCED NSCLC

  

 

 

 

 

 

 

 

Implications of the new IASLC staging system and adenocarcinoma classification for systemic treatment of NSCLC - Eric Lim, MB, ChB, MD, MSc, FRCS (C-Th)

Molecular profiling and personalized medicine for patients with lung cancer - David Gandara, MD

The relevance of histological diagnosis in making treatment decisions - Giorgio Scagliotti, MD

Making NSCLC a chronic disease: reality or dream? - Tony Mok, MD

New targets for lung cancer - Suresh Ramalingam, MD

 

UNDERSTANDING IMMUNOTHERAPEUTIC APPROACHES IN NSCLC 

 

 

 

 

 

 

 

 

 

 

 

Basic Concepts in Immunology - Dmitry Gabrilovich, MD, PhD

Immunomodulators for NSCLC - David Carbone, MD, PhD

Vaccines for NSCLC - Johan Vansteenkiste, MD, PhD

COMMITTEE SELF-NOMINATION PROCESS OPEN FOR MEMBERS

The IASLC seeks a highly competent and active pool of members to serve as volunteers on its organizational committees. IASLC Committees contribute significantly to the effective operation and development of IASLC programs.  If you are an active member of IASLC, with interest to serve on a committee, please visit the Committee Page for more information.

 

UPCOMING MEETINGS

 

July 25-27, 2013

14th International Lung Cancer Congress

Huntington Beach, California

More information: www.gotoper.com 

 

 

15th World Conference on Lung Cancer October 27-30, 2013 Sydney, Australia

 

 

ADVOCACY TRAVEL AWARDS

The IASLC invites patient advocates to apply for the organization’s Advocacy Travel Awards. The IASLC will offer travel awards to a limited number of patient advocates to participate in the World Conference on Lung Cancer (WCLC) Oct. 27-30, 2013 in Sydney, Australia. Full details regarding the application process and eligibility selection are on the WCLC Website.

 

About Iaslc 

 

The Denver-based International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 3,500 lung cancer specialists in 80 countries.

 

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

 

Our mission:

• to embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies

• to provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public

• to use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world